Reporting onsite from AACR 2022 in New Orleans, Nicolas Girard discusses practice changing results from the CheckMate 816 trial involving the addition of neoadjuvant nivolumab to chemotherapy for resectable (IB-IIIA) NSCLC. He further reviews the encouraging results at 2 years from CodeBreaK100 with sotorasib in pretreated patients with KRASp.G12C-mutated NSCLC.
Abstracts:
- CT012 - Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial - Nicolas Girard, et al.
- CT008 - Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 - Grace K. Dy, et al.

Produced by the European Society for Medical Oncology
[ Ссылка ]

свернуть